LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases 2022.01.07

 

Cision PR Newswire: news distribution, targeting and monitoring home 

 

 

LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases

News provided by

Jan 06, 2022, 09:00 ET

 


 

SEOUL, South Korea, Jan. 6, 2022 /PRNewswire/ -- LISCure Biosciences Inc., a leading biotech

focused on microbial-based therapeutics, announced that it has executed a research collaboration

agreement with Mayo Clinic for new drug development for rare liver diseases.

 

LISCure has been conducting joint research with Mayo Clinic for NASH drugs since 2021, and this

new collaboration is an agreement signed under the leadership of Nicholas F. LaRusso, M.D. and

Steven P. O'Hara, Ph.D., renowned authorities in the field of rare liver diseases.

 

Under the terms of the agreement, Mayo Clinic and LISCure metabolic disease R&D teams will

collaborate on preclinical and clinical studies for rare liver diseases including primary sclerosing

cholangitis (PSC), a cholestatic liver disease characterized by chronic liver inflammation and the

progressive destruction of bile ducts.

 

PSC is an orphan disease of which prevalence ranges from 3 to 16 per 100,000. Unfortunately,

apart from liver transplantation, there are no approved drugs targeting the condition in practical

medical use. Mayo Clinic and LISCure research teams recognized the importance of a microbiome-

based therapeutic approach in PSC treatment and decided to jointly research the efficacy and

additional mechanisms of LISCure's drug candidates.

 

"LB-P8 program is currently in clinical trials based on the promising results from various animal

models of NASH. We aim to expand our pipeline into rare disease through this research

collaboration with Mayo Clinic for PSC," said Hwasup Chin, CEO of LISCure. "Based on this long-

term collaboration, we seek to provide new treatments to patients with rare liver diseases." He

continues, "we have a new drug candidate in preclinical studies for idiopathic pulmonary fibrosis

and expect to enter a clinical trial in 2023."

 

LISCure plans to initiate phase 2 clinical trial in the US for LB-P8 in 2H 2022.

 

SOURCE LISCure Biosciences Inc.


View original content >>